(Q37876521)

24 August 2017

1 reference

title

Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling (English)

1 reference

24 August 2017

Joost J Leenders

1

1 reference

24 August 2017

Yigal M Pinto

series ordinal

2

1 reference

24 August 2017

Esther E Creemers

series ordinal

3

1 reference

24 August 2017

publication date

7 May 2011

1 reference

Journal of Molecular and Cellular Cardiology

24 August 2017

published in

1 reference

24 August 2017

volume

51

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

156-167

1 reference

Molecular mechanisms of myocardial remodeling

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Cardiac hypertrophy: the good, the bad, and the ugly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Genetic dissection of cardiac growth control pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Negative regulators of cardiac hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MicroRNA-133 controls cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Control of stress-dependent cardiac growth and gene expression by a microRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MicroRNAs and cardiac pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MicroRNAs add a new dimension to cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Diverse physiological functions for dual-specificity MAP kinase phosphatases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Small GTP-binding proteins and their regulators in cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Cdc42 is an antihypertrophic molecular switch in the mouse heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Activation mechanism of the MAP kinase ERK2 by dual phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Calsarcins, a novel family of sarcomeric calcineurin-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Protein kinase cascades in the regulation of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Protein kinase C in heart failure: a therapeutic target?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

PICOT: a multidomain scaffolding inhibitor of hypertrophic signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Biological control through regulated transcriptional coactivators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Control of cardiac growth by histone acetylation/deacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Control of muscle development by dueling HATs and HDACs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Thioredoxin1 as a negative regulator of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Targeting histone deacetylases for heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Myocardin induces cardiomyocyte hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

7 January 2021

Sirtuins at a glance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Sirt1 regulates aging and resistance to oxidative stress in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Oxidative stress and redox signalling in cardiac hypertrophy and heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Krüppel-like transcription factors: a functional family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Transcriptional regulation of the CLC-K1 promoter by myc-associated zinc finger protein and kidney-enriched Krüppel-like factor, a novel zinc finger repressor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The Krüppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Smooth and cardiac muscle-selective knock-out of Kruppel-like factor 4 causes postnatal death and growth retardation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Histone deacetylase inhibition in the treatment of heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Deletion of cytosolic phospholipase A2 promotes striated muscle growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

KChIP2 attenuates cardiac hypertrophy through regulation of Ito and intracellular calcium signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Post-translational regulation of calsarcin-1 during pressure overload-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

A20 is dynamically regulated in the heart and inhibits the hypertrophic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

S100beta inhibits alpha1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

c-Flip overexpression reduces cardiac hypertrophy in response to pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Myocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme oxygenase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

CHF1/Hey2 promotes physiological hypertrophy in response to pressure overload through selective repression and activation of specific transcriptional pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.04.017

10.1016/J.YJMCC.2011.04.017

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference